AVITA Medical Raises 2026 Guidance, Sees Cash Flow Breakeven in Q4
RCEL sits 75% above its 52-week low of $3.22.
Summary
AVITA Medical raised its full-year 2026 revenue guidance to $86M-$89M from $80M-$85M after record Q2 revenue of $21.7M, up 18% YoY. The company now expects to reach cash flow breakeven in Q4 2026, a significant milestone given its going concern warning and only $11.1M in cash at quarter-end. Quarterly net cash use dropped sharply to ~$3.2M from $9.9M in Q1, driven by 81.9% gross margins and a 6% decline in operating expenses. A CMS proposal for 2027 Medicare payment changes would establish national physician reimbursement for RECELL, potentially reducing variability and supporting adoption. This follows the Q2 8-K filed earlier today, but the guidance raise and breakeven timeline are new, material developments that strengthen the near-term outlook.
At the time of this announcement, RCEL was trading at $5.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.2M. The 52-week trading range was $3.22 to $7.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Small Caps.